JP2020536092A - 細菌感染症の治療方法 - Google Patents

細菌感染症の治療方法 Download PDF

Info

Publication number
JP2020536092A
JP2020536092A JP2020519066A JP2020519066A JP2020536092A JP 2020536092 A JP2020536092 A JP 2020536092A JP 2020519066 A JP2020519066 A JP 2020519066A JP 2020519066 A JP2020519066 A JP 2020519066A JP 2020536092 A JP2020536092 A JP 2020536092A
Authority
JP
Japan
Prior art keywords
subject
meropenem
administered
bavolbactam
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020519066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536092A5 (https=
Inventor
エリザベス アレクサンダー
エリザベス アレクサンダー
ジェフ ルーティット
ジェフ ルーティット
マイケル エヌ． ダドリー
マイケル エヌ． ダドリー
Original Assignee
メリンタ セラピューティクス インコーポレイテッド
メリンタ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65994826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2020536092(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by メリンタ セラピューティクス インコーポレイテッド, メリンタ セラピューティクス インコーポレイテッド filed Critical メリンタ セラピューティクス インコーポレイテッド
Publication of JP2020536092A publication Critical patent/JP2020536092A/ja
Publication of JP2020536092A5 publication Critical patent/JP2020536092A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020519066A 2017-10-03 2018-10-01 細菌感染症の治療方法 Pending JP2020536092A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762567702P 2017-10-03 2017-10-03
US62/567,702 2017-10-03
US201862657402P 2018-04-13 2018-04-13
US62/657,402 2018-04-13
PCT/US2018/053772 WO2019070591A1 (en) 2017-10-03 2018-10-01 METHODS OF TREATING BACTERIAL INFECTIONS

Publications (2)

Publication Number Publication Date
JP2020536092A true JP2020536092A (ja) 2020-12-10
JP2020536092A5 JP2020536092A5 (https=) 2021-11-11

Family

ID=65994826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020519066A Pending JP2020536092A (ja) 2017-10-03 2018-10-01 細菌感染症の治療方法

Country Status (16)

Country Link
US (3) US11376237B2 (https=)
EP (1) EP3691652A4 (https=)
JP (1) JP2020536092A (https=)
KR (1) KR20200066664A (https=)
CN (1) CN111432821A (https=)
AU (1) AU2018345317B2 (https=)
BR (1) BR112020006658A2 (https=)
CA (1) CA3078238A1 (https=)
CL (1) CL2020000892A1 (https=)
JO (1) JOP20200075A1 (https=)
MX (1) MX2020003670A (https=)
MY (1) MY200934A (https=)
PH (1) PH12020550249A1 (https=)
SG (1) SG11202003009QA (https=)
TW (2) TW201922241A (https=)
WO (1) WO2019070591A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511054A (ja) * 2021-03-24 2024-03-12 トラスティーズ オブ タフツ カレッジ ボロン酸化合物、組成物および方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11376237B2 (en) 2017-10-03 2022-07-05 Melinta Subsidiary Corp. Methods of treating bacterial infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018129479A1 (en) * 2017-01-09 2018-07-12 Rempex Pharmaceuticals, Inc Methods of treating bacterial infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912363A (zh) 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
CA2807546C (en) 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN102188395B (zh) 2011-04-29 2012-12-05 石药集团中诺药业（石家庄）有限公司 一种更稳定的美罗培南注射剂及其制备方法
CN102335136B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种供注射用美罗培南药物组合物及其制备方法
CN102335137B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种含美罗培南的药物组合物
CN102525961B (zh) 2012-01-17 2013-02-13 山东罗欣药业股份有限公司 美罗培南组合物注射用粉针剂
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN103570718B (zh) 2012-07-31 2016-06-29 深圳市海滨制药有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
RU2675847C2 (ru) 2013-05-28 2018-12-25 Морфохем Акциенгезельшафт Фюр Комбинаторише Хеми Комбинированные терапевтические средства, содержащие оксазолидинон-хинолоны, предназначенные для лечения бактериальных инфекций
WO2016172208A1 (en) 2015-04-24 2016-10-27 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
CN108289896B (zh) 2015-07-09 2022-03-01 华盛顿大学 抗菌药物组合的组合物和使用方法
US9949995B2 (en) 2015-09-04 2018-04-24 Case Western Reserve University Compositions and methods of treating of bacterial infections with β-lactamase inhibitors
US11376237B2 (en) * 2017-10-03 2022-07-05 Melinta Subsidiary Corp. Methods of treating bacterial infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018129479A1 (en) * 2017-01-09 2018-07-12 Rempex Pharmaceuticals, Inc Methods of treating bacterial infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANTIMICROB. AGENTS CHEMOTHER., vol. 60, no. 9, JPN6022042324, 2016, pages 5454 - 5458, ISSN: 0005068992 *
DRUGS TODAY, vol. 53(10), JPN7023002041, October 2017 (2017-10-01), pages 521 - 530, ISSN: 0005253247 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511054A (ja) * 2021-03-24 2024-03-12 トラスティーズ オブ タフツ カレッジ ボロン酸化合物、組成物および方法

Also Published As

Publication number Publication date
AU2018345317B2 (en) 2024-10-24
CA3078238A1 (en) 2019-04-11
EP3691652A1 (en) 2020-08-12
US11376237B2 (en) 2022-07-05
US20200297695A1 (en) 2020-09-24
JOP20200075A1 (ar) 2020-04-30
AU2018345317A1 (en) 2020-05-07
PH12020550249A1 (en) 2021-02-15
KR20200066664A (ko) 2020-06-10
EP3691652A4 (en) 2021-07-07
MY200934A (en) 2024-01-24
US20220288024A1 (en) 2022-09-15
CN111432821A (zh) 2020-07-17
CL2020000892A1 (es) 2020-10-23
BR112020006658A2 (pt) 2020-09-24
SG11202003009QA (en) 2020-04-29
WO2019070591A1 (en) 2019-04-11
US12533342B2 (en) 2026-01-27
MX2020003670A (es) 2020-08-03
US20260102374A1 (en) 2026-04-16
TW202400146A (zh) 2024-01-01
TW201922241A (zh) 2019-06-16

Similar Documents

Publication Publication Date Title
US20260102374A1 (en) Methods of treating bacterial infections
WO2020043185A1 (zh) 氨基酸类营养素的应用以及包含它的药物组合物
US20160000793A1 (en) Sodium channel blocker for treatment of loss of superficial sensitivity
TWI468161B (zh) 組合藥劑之醫藥產品、試劑及用途
US20260069595A1 (en) Formulation of delgocitinib in the form of a cream
CN115463118A (zh) 和厚朴酚在制备治疗或预防毛细血管瘤的药物中的用途
US11141421B2 (en) Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
WO2024120523A1 (zh) 一种治疗前列腺癌的药物组合及其应用
CA3071096A1 (en) Co-administration of minocycline and colistin to reduce acute kidney injury
US20210052608A1 (en) Methods of treating bacterial infections with minocycline
US20250241976A1 (en) Administration of an anticancer peptide
US9314437B2 (en) Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (NDGA)
WO2024073672A1 (en) Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
WO2025064688A1 (en) Sparsentan for treating immunoglobulin a nephropathy (igan)
CN119522109A (zh) 用于钙调磷酸酶抑制剂的间歇性给药的组合物
US20090247498A1 (en) Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications
HK1185808B (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200511

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230529

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230822

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240205